Semax: Cognitive Enhancement Peptide from Russian…

Semax is a heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the 4–10 fragment of adrenocorticotropic hormone (ACTH). Despite its ACTH origin, semax has no corticotropic activity — it does not stimulate cortisol release. Instead, it has been developed for its potent nootropic, neuroprotective, and neurotrophic properties. Like selank, semax was developed by the Institute of Molecular Genetics of the Russian Academy of Sciences and is registered in Russia and Ukraine for clinical use, giving it a regulatory standing uncommon among international research peptides.

History and Clinical Status

Semax was developed in the 1980s and entered Russian clinical practice in the 1990s. It is registered in Russia as a drug for:

Memory and cognitive function improvement
Stroke rehabilitation and ischemic brain injury
Attention deficit in children
Normalization of cerebral blood flow after subarachnoid hemorrhage

This clinical registration means semax has been through formal efficacy and safety evaluation — a significant distinction from purely research compounds. It is available as a nasal spray in Russian pharmacies and exported internationally as a research compound.

Mechanism of Action

Semax's cognitive and neuroprotective effects arise from multiple mechanisms:

BDNF elevation: The most well-documented effect of semax is its ability to significantly upregulate BDNF (brain-derived neurotrophic factor) in the cortex, hippocampus, and other brain regions. BDNF is the primary neurotrophin governing synaptic plasticity, long-term potentiation (LTP), and neuronal survival. A single intranasal dose of semax in rats increases hippocampal BDNF 5–8-fold within hours — an effect that persists for 24+ hours. This is one of the most potent BDNF-elevating effects documented for any compound.

BDNF receptor (TrkB) activation: Semax also upregulates expression of the TrkB receptor, meaning the neural tissue becomes more sensitive to both endogenous and semax-induced BDNF.

Dopaminergic enhancement: Semax increases dopamine release and dopamine receptor sensitivity in the prefrontal cortex — a mechanism that contributes to its effects on working memory, motivation, and focus.

Serotonergic modulation: Semax modulates serotonin turnover in limbic regions, contributing to its subtle mood-stabilizing and anxiolytic properties.

Neuroprotection: In ischemia models, semax reduces infarct size, preserves neuronal viability, and reduces inflammation in ischemic penumbra tissue. The mechanisms include reduction of reactive oxygen species, decreased NF-kB activation, and preservation of mitochondrial function.

Forms of Semax

Standard semax (Met-Glu-His-Phe-Pro-Gly-Pro): The original formulation. Nootropic and anxiolytic/mood-stabilizing.

N-acetyl semax: An acetylated form with modestly different pharmacokinetics and reduced receptor desensitization. Some users prefer it for longer cycles.

N-acetyl semax amidate: Further modified with C-terminal amidation for enhanced stability and potency. Considered the most potent and longest-acting form.

Semax amidate: C-terminal amidation increases CNS half-life by slowing peptidase degradation.

The amidate and acetylated forms are typically dosed at approximately 60–70% of standard semax doses due to increased potency.

Dosage and Administration

Intranasal (most common):

200–900 mcg per session
0.1% solution: 1 mg/mL; each drop from a standard nasal dropper delivers approximately 20–25 mcg
For 600 mcg: approximately 3 drops per nostril
1–3 sessions per day
Russian clinical protocols: 500–1,500 mcg/day in divided doses for 10–14 days

Subcutaneous injection:

100–600 mcg per injection
Provides higher bioavailability than intranasal for systemic effects; intranasal is preferred for direct CNS delivery
1–2 injections daily

Half-life: Semax is metabolized rapidly (minutes) in blood. However, its CNS effects, mediated by the persistent BDNF elevation and receptor changes, last substantially longer than plasma levels would suggest.

Effects Profile

Users and clinical data describe:

Acute effects (within 30–90 minutes):

Enhanced focus and mental clarity
Improved verbal fluency and word retrieval
Increased motivation and drive
Mild stimulant-like quality (without the anxiety or heart rate effects of conventional stimulants)

Chronic effects (with regular dosing over days to weeks):

Improved working memory and learning speed
Enhanced stress resilience and emotional stability
Reduced mental fatigue during prolonged cognitive tasks
Neuroprotective accumulation of BDNF

Stroke and Neuroprotection Application

The most evidence-supported clinical use of semax is in ischemic stroke recovery. Russian clinical trials show semax administered within 24 hours of ischemic stroke significantly reduces the volume of brain injury (measured on MRI), improves neurological outcome scores, and accelerates motor and cognitive recovery. The mechanism involves both anti-inflammatory effects in the ischemic penumbra and BDNF-driven neuroplasticity in surviving tissue.

This neuroprotective application drives interest in semax as a preventive intervention for people with high cerebrovascular risk, though no prospective trials exist for this indication.

Comparison to Other Nootropic Peptides

Semax vs. Selank: Semax is more activating and cognitively stimulating; selank is more calming and anxiolytic. Many practitioners combine them or use semax for cognitive work and selank for evening anxiety management.

Semax vs. Dihexa: Dihexa is a much smaller, more potent nootropic peptide that also elevates BDNF. Dihexa is more potent per molecule but has a more complex and less studied safety profile than semax.

FAQ

Does semax increase cortisol? Despite being derived from ACTH, semax lacks the corticotropic activity of the parent hormone. Multiple studies confirm semax does not stimulate adrenal cortisol release at any tested dose.

How long should I use semax before expecting cognitive benefits? Some users report acute effects within the first session. The full nootropic benefit — driven by sustained BDNF elevation and synaptic remodeling — typically emerges after 5–14 days of consistent use. Russian clinical protocols use 10–14 day courses followed by breaks.

Is semax safe for long-term use? Russian clinical data spanning decades of use supports good tolerability. No serious adverse events are consistently reported. The main practical concern is desensitization with continuous use — cycling (10–14 days on, 1–2 weeks off) is recommended to maintain efficacy.

Track your supplements in Optimize.

Semax: Cognitive Enhancement Peptide from Russian Nootropics Research